SCHEMBL25544142

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)C(C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)C(C)NC(=O)[C@H](CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)[C@@H](NC(=O)C(NC(=O)[C@H](CCCNC(=N)N)NC(=O)C(Cc1ccccc1)NC(=O)C(CCCCNNC(Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)NC(CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)NC(C=O)CO)[C@@H](C)O)NC)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(N)=O

nearest known ligand 0.63

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	NPY2R	P49146	8/20	0.59

▸	NPY4R	P50391	8/20	0.59

▸	NPY5R	Q15761	8/20	0.59

▸	NPY1R	P25929	6/20	0.58

▸	TFPI	P10646	6/20	0.57

▸	KDM1A	O60341	2/20	0.56

▸	MAPK8	P45983	1/20	0.55

▸	MAPK9	P45984	1/20	0.55

▸	MAPK10	P53779	1/20	0.55

▸	EP300	Q09472	1/20	0.53

▸	HIF1A	Q16665	1/20	0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL12038559	0.97	NPY2R (0.59)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL12038572	0.95	NPY2R (0.52)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL12038621	0.95	NPY2R (0.59)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL12038668	0.95	NPY2R (0.59)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL29361579	0.89	NPY2R (0.56)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL12038577	0.89	NPY2R (0.60)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL12038607	0.88	EED (0.52)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL12038596	0.88	NPY2R (0.61)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL16589778	0.87	VIPR1 (0.51)	NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL12038635	0.87	KDM1A (0.55)	TFPIKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20240025980-A1	THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES	Orionis Biosciences BV (BE)	2024-01-25	—	—	US	disclosed
US-20230399406-A1	TARGETED THERAPEUTIC AGENTS AND USES THEREOF	Orionis Biosciences BV (BE)	2023-12-14	—	—	US	disclosed
US-11753463-B2	Therapeutic targeting of non-cellular structures	Orionis Biosciences BV (BE)	2023-09-12	—	—	US	disclosed
US-11702477-B2	Bi-functional chimeric proteins and uses thereof	Orionis Biosciences BV (BE)	2023-07-18	—	—	US	disclosed
US-11661455-B2	Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety	Orionis Biosciences BV (BE)	2023-05-30	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11702477-B2	Bi-functional chimeric proteins and uses thereof	BCR, HAVCR2, CD2BP2	NPY2R 4118/4885NPY4R 4101/4885NPY5R 3826/4885
US-11753463-B2	Therapeutic targeting of non-cellular structures	CD47, HAVCR2, BCR	NPY2R 4667/4885NPY4R 4701/4885NPY5R 4471/4885
US-20240025980-A1	THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES	CD47, HAVCR2, BCR	NPY2R 4667/4885NPY4R 4701/4885NPY5R 4471/4885
US-11661455-B2	Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety	IFNG, IL2RA, IFNAR1	NPY2R 4088/4885NPY4R 4589/4885NPY5R 4559/4885
US-20230399406-A1	TARGETED THERAPEUTIC AGENTS AND USES THEREOF	CD47, HAVCR2, CD74	NPY2R 3987/4885NPY4R 3740/4885NPY5R 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.